AMT-260

AMT-260 gene therapy · UniQure Biopharma B.V.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AMT-260, covering 2026-04-06 to 2026-04-06. Get the full timeline:

Most recent: Clinical Trial Update: AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy [Phase 1, Phase 2]